Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
Summary
Third Opinion Trial Synopsis:
This study will check how safe and tolerable VP301 is and how it moves through the body in people who have cancer that came back after treatment or did not respond well to treatment.
This study will check how safe and tolerable VP301 is and how it moves through the body in people who have cancer that came back after treatment or did not respond well to treatment.
*Third Opinion AI Generated Synopsis
Trial Summary
This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.
This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
